Company profile

Tectonic Therapeutic, Inc.

Pipeline3 assets

TX45TX-000045 / RXFP1 / Fc-relaxin fusion protein / Cardiopulmonary
PH-HFpEF (Group 2 Pulmonary Hypertension)PH-HFrEF (Group 2 Pulmonary Hypertension)PH-ILD (Group 3 Pulmonary Hypertension)
TX2100TX002100 / GPCR / Biotherapeutic / GPCR Antagonist / Hematology / Rare Diseases
Hereditary Hemorrhagic Telangiectasia (HHT)
Fibrosis ProgramGPCR / Bispecific GPCR Antagonist / Fibrosis
Fibrosis

Latest news6 items

Sep 29, 2026

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S. TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally

Trial Results • Phase 1Results event Tue, Sep 29, 2026

Sep 3, 2026

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs),

Aug 6, 2026

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1 2027 TX45 APEX Phase 2 clinical trial Independent Data Monitoring Committee

Enrollment • Phase 2Enrollment completion Tue, Jun 30, 2026

Jun 10, 2026

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched

Enrollment • Phase 2Enrollment milestone Wed, Jun 10, 2026

May 7, 2026

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”), and as

Enrollment • Phase 2

Apr 23, 2026

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs),